(NASDAQ: AGRX) Agile Therapeutics's forecast annual revenue growth rate of 107.03% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 11.52%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.77%.
Agile Therapeutics's revenue in 2023 is $8,403,000.On average, 1 Wall Street analysts forecast AGRX's revenue for 2023 to be $983,683,844, with the lowest AGRX revenue forecast at $983,683,844, and the highest AGRX revenue forecast at $983,683,844. On average, 1 Wall Street analysts forecast AGRX's revenue for 2024 to be $1,907,664,333, with the lowest AGRX revenue forecast at $1,907,664,333, and the highest AGRX revenue forecast at $1,907,664,333.
In 2025, AGRX is forecast to generate $3,068,021,370 in revenue, with the lowest revenue forecast at $3,068,021,370 and the highest revenue forecast at $3,068,021,370.